Azeloprazole

Azeloprazole

SCHEMBL4333430

Cc1cnc(C[S@+]([O-])c2nc3ccccc3[nH]2)c(C)c1OCC1COC(C)(C)OC1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
WDR5 P61964 3/20 0.40
SARM1 Q6SZW1 1/20 0.40
ATP4A P20648 2/20 0.33
ATP4B P51164 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.31
BRS3 P32247 2/20 0.31
AR P10275 1/20 0.31
APP P05067 1/20 0.31
MEN1 O00255 1/20 0.30
CYP2C9 P11712 2/20 0.30
KDM4E B2RXH2 1/20 0.30
DDAH1 O94760 1/20 0.30
ABCB11 O95342 1/20 0.30
ALDH1A1 P00352 1/20 0.30
ATP1A1 P05023 1/20 0.30
ATP1B1 P05026 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azeloprazole SCHEMBL710150 1.00 KMT2A (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL31312701 1.00 KMT2A (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL4333414 1.00 KMT2A (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL4492343 0.99 WDR5 (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL4336045 0.99 WDR5 (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL4338561 0.99 WDR5 (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL711094 0.99 WDR5 (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL4338563 0.99 WDR5 (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL711093 0.99 WDR5 (0.40) KMT2AWDR5SARM1ATP4AATP4B
Azeloprazole SCHEMBL4336050 0.99 WDR5 (0.40) KMT2AWDR5SARM1ATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090182149-A1 SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-07-16 US disclosed
EP-2077265-A1 SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF Eisai R&D Management Co., Ltd. (JP) 2009-07-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182149-A1 SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF BRI3BP, SNRK, SRI KMT2A 500/4885WDR5 1543/4885SARM1 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.